Quick answer
What is semaglutide's chemical structure, and how is it made? Semaglutide is a 31-residue analog of human GLP-1(7–37) with an α-aminoisobutyric acid (Aib) at position 8, arginine in place of lysine at position 34, and a C18 fatty diacid attached through a γ-glutamic acid and short hydrophilic spacer to lysine 26. The substitutions block enzymatic cleavage; the lipid binds albumin. Research-grade material is generally assembled by stepwise solid-phase peptide synthesis, cleaved from the resin, purified by reversed-phase HPLC and freeze-dried. The semaglutide product page lists the molecular formula C187H291N45O59 for the 10 mg lyophilized vial. For laboratory research use only.
Most semaglutide articles stop at "GLP-1 receptor agonist". For a laboratory the structure and the route of manufacture matter more, because they explain the impurity profile, the solution behavior and the analytical checks worth running. This guide walks through the molecule residue by residue, then through how a long, lipidated peptide is assembled and purified. Pharmacology and handling are covered in the semaglutide research overview and are mentioned here only where chemistry explains them.
The backbone: a modified GLP-1
Native GLP-1(7–37) is a 31-residue peptide that is cleared within minutes because dipeptidyl peptidase-4 removes its two N-terminal residues and because it is filtered and degraded elsewhere. Lau and colleagues (2015) describe how semaglutide was derived from it by a short list of deliberate changes. A narrower history is in Knudsen and Lau (2019).
| Position | Native GLP-1(7–37) | Semaglutide | Purpose of the change |
|---|---|---|---|
| 8 | Alanine | Aib (α-aminoisobutyric acid) | Hinders cleavage by dipeptidyl peptidase-4 at the N-terminus |
| 26 | Lysine | Lysine, acylated on the side chain | Attachment point for the lipid-bearing side chain |
| 34 | Lysine | Arginine | Leaves a single lysine free for selective acylation |
| Side chain | None | C18 fatty diacid, γ-glutamic acid, two short hydrophilic spacer units | Reversible albumin binding, slower clearance |
| C-terminus | Glycine, free acid | Glycine, free acid | Unchanged |
Two points follow. First, the unusual residue (Aib) cannot be produced by ordinary biological expression of the unmodified gene, which is relevant to how the molecule can be made. Second, replacing lysine 34 with arginine is a synthetic convenience as much as a stability measure: it leaves a single reactive amine for the acylation step, so the lipid goes to one position only.
The side chain and why it dominates handling
The substituent on lysine 26 is the feature that sets semaglutide apart from simpler analogs. It combines a long fatty diacid, a γ-glutamic acid linker and a flexible hydrophilic spacer. The diacid end binds albumin; the spacer keeps the lipid from interfering with receptor engagement. The consequence at the bench is that the molecule is amphiphilic. It tends to adsorb to hydrophobic surfaces, to foam when agitated and, at high concentration, to self-associate. Gentle swirling, low-binding plasticware and few transfers are not fussy habits but direct consequences of this side chain.
Metabolism studies show the same architecture from the other side. Jensen and colleagues (2017) reported that in humans and in rats and monkeys intact semaglutide was the main circulating component, and that metabolism proceeded through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain. For a chemist that is a useful reminder that the two halves of the molecule have different weak points, and that degradation products can be peptide fragments, side-chain fragments or both.
Molecular formula and what it does and does not tell you
The product page for the 10 mg vial lists the formula C187H291N45O59. Summing average atomic masses gives about 4,114 g/mol for the free peptide. That value is the figure for concentration arithmetic where the molecular weight is needed, but three caveats apply. The vial holds counterions from purification, commonly trifluoroacetate or acetate, plus residual water, so the mass of peptide in a vial is less than the labelled mass if the label counts the whole powder (Sikora and colleagues, 2020 review the role of counterions). Sequence identity is not proven by formula alone, because isomers, truncated forms and deletion sequences can share or nearly share a mass. And purity by HPLC describes chromatographic composition, not net peptide content.
The product page states that sequence and identity are reported on the certificate of analysis where published. The COA library lists what is available, and how to read a COA explains each field.
How a long lipidated peptide is assembled
Merrifield (1963) introduced solid-phase peptide synthesis: the C-terminal residue is anchored to an insoluble resin and the chain is extended one protected amino acid at a time, with excess reagents washed away after each coupling. The modern version uses Fmoc chemistry for the α-amino group and acid-labile protecting groups on side chains, a strategy reviewed in detail by Isidro-Llobet, Álvarez and Albericio (2009). For a 31-residue peptide with a non-natural residue and a lipid side chain the sequence of operations is typically:
- Anchor the first residue to a resin and extend the chain from the C-terminus with protected amino acids, including Aib, which is sterically hindered and couples slowly.
- Introduce lysine 26 with an orthogonal side-chain protecting group that can be removed without cleaving the rest.
- Remove that group selectively on the resin and couple the spacer, the glutamic acid linker and the fatty diacid in order.
- Cleave the peptide from the resin with strong acid, which also removes the remaining side-chain protecting groups.
- Purify by preparative reversed-phase HPLC, pool fractions that meet the acceptance criterion, and freeze-dry.
Other routes exist, including combinations of recombinant expression of the backbone with chemical acylation, and a laboratory cannot assume which route made a given lot. What it can do is ask what impurities the route implies and test for them.
Impurities that the chemistry predicts
| Impurity class | Origin | Why it matters |
|---|---|---|
| Deletion sequences | Incomplete coupling at a hindered residue such as Aib | Lower potency or altered binding while co-eluting close to the main peak |
| Truncated chains | Capping or failed couplings | Lower apparent purity, different mass |
| Diastereomers (racemization) | Base- or activation-induced epimerization at a residue | Same mass, altered activity; difficult to resolve |
| Mis-acylated or di-acylated forms | Lipid attached at an unintended amine | Changes albumin binding and solubility |
| Oxidation products | Exposure to air or peroxides in solvents | Mass shift of +16 per oxidized residue |
| Deamidation or isomerization | Aging in solution, especially at higher pH | Charge and conformation change |
| Residual solvents and counterions | Cleavage and purification reagents | Reduce net peptide content, may affect cell assays |
D'Hondt and colleagues (2014) review this class of process-related and degradation-related impurities in peptide medicines. For a researcher the lesson is that a single HPLC percentage conceals a population of related species. Reading the chromatogram, not only the headline figure, is how to spot a shoulder or a late-eluting lipid-related peak.
Analytical checks that follow from the structure
Each structural feature suggests a test. Reversed-phase HPLC separates the product from most truncated and deleted species, and the long gradient needed for an amphiphilic peptide is itself a clue to column choice. Mass spectrometry confirms the intact mass and, with fragmentation, the position of the lipid and the Aib residue; it is the orthogonal check to chromatography, discussed in HPLC vs mass spectrometry. Amino acid analysis or UV against a known extinction coefficient estimates net peptide content. Karl Fischer titration or thermogravimetry measures water, and ion chromatography measures counterions. A laboratory seldom needs all of them, but any assay whose result depends on absolute concentration should include at least one content measurement. See also semaglutide purity testing and understanding HPLC purity.
From structure to storage and solution behavior
The chemistry points to a handling approach. As a freeze-dried solid the peptide avoids hydrolysis, deamidation and oxidation, which require water, so powder is the stable form. The product page states storage at 2–8 °C, or −20 °C for long-term holding, protected from heat, moisture and light. Once dissolved, the amphiphilic side chain encourages adsorption and aggregation, so solutions should be prepared gently, kept cold and used soon; frozen single-use portions avoid repeated freeze–thaw. Concentration is a formula: vial mass divided by diluent volume, then divided by molecular weight for molar form. The reconstitution calculator performs the arithmetic, semaglutide reconstitution and handling gives the bench method, and semaglutide storage and stability covers shelf-life questions.
The vial is a sealed clear glass research container and the product is supplied as lyophilized powder. Other materials in the same category are in the shop, and related reading includes what is sema (semaglutide) peptide and GLP-1 receptor agonists in research.
A note on reading structural claims
Structural statements in secondary sources are sometimes loose: residue numbering that mixes the GLP-1(1–37) and (7–37) conventions, side-chain descriptions that omit the linker, or formulas copied from a different salt form. When a design depends on the structure, return to the primary paper, count residues yourself and compare the formula with the sequence. A thirty-minute check of this kind is cheaper than discovering after the fact that two groups were describing different molecules under the same name. Record the source of every structural fact in the notebook beside the lot number.
Frequently asked questions
How many amino acids does semaglutide have?
Its backbone is a 31-residue analog of human GLP-1(7–37), modified at position 8 (Aib) and position 34 (arginine), with a lipid side chain on lysine 26.
What is the molecular formula on the product page?
C187H291N45O59, giving an average mass of about 4,114 g/mol for the free peptide.
What does the Aib residue do?
It hinders cleavage by dipeptidyl peptidase-4 at the N-terminus, which makes the backbone more persistent in biological media.
Why is lysine 34 replaced by arginine?
It leaves one lysine available for selective attachment of the side chain, and the change was part of the analog design described in the discovery literature.
How is research-grade semaglutide generally made?
Usually by stepwise solid-phase peptide synthesis with Fmoc chemistry, followed by acid cleavage, reversed-phase HPLC purification and freeze-drying. Other routes exist.
Why does semaglutide foam or stick to plastic?
Its fatty diacid side chain makes it amphiphilic. Gentle swirling and low-binding plasticware limit foaming and loss.
Is HPLC purity the same as peptide content?
No. HPLC purity describes chromatographic composition. Counterions and water also occupy vial mass, so net peptide content is a separate figure.
What impurities should I expect from the chemistry?
Deletion and truncated sequences, diastereomers, mis-acylated forms, oxidation products, deamidation products and residual solvents or counterions.
How is the vial stored?
The product page states 2–8 °C, or −20 °C for long-term holding, protected from heat, moisture and light.
Where can I verify identity?
On the certificate of analysis where published, through the COA library. Mass spectrometry is the orthogonal check to HPLC.
Research-use statement
All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside the laboratory.
References
- Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. doi:10.3389/fendo.2019.00155
- Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31-41. doi:10.1016/j.ejps.2017.03.020
- Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025
- Isidro-Llobet A, Álvarez M, Albericio F. Amino acid-protecting groups. Chem Rev. 2009;109(6):2455-2504. doi:10.1021/cr800323s
- D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. doi:10.1016/j.jpba.2014.06.012
- Sikora K, Jaśkiewicz M, Neubauer D, Migoń D, Kamysz W. The role of counter-ions in peptides—an overview. Pharmaceuticals. 2020;13(12):442. doi:10.3390/ph13120442
